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ARTICLE
Genome Scan for Tourette Disorder in Affected-Sibling-Pair
and Multigenerational Families
The Tourette Syndrome Association International Consortium for Genetics*
Tourette disorder (TD) is a neuropsychiatric disorder with a complex mode of inheritance and is characterized by multiple
waxing and waning motor and phonic tics. This article reports the results of the largest genetic linkage study yet
undertaken for TD. The sample analyzed includes 238 nuclear families yielding 304 “independent” sibling pairs and 18
separate multigenerational families, for a total of 2,040 individuals. A whole-genome screen with the use of 390 micro-
satellite markers was completed. Analyses were completed using two diagnostic classifications: (1) only individuals with
TD were included as affected and (2) individuals with either TD or chronic-tic (CT) disorder were included as affected.
Strong evidence of linkage was observed for a region on chromosome 2p ( , ) in the analyses555 logPp 4.42 Pp 3.8# 10
that included individuals with TD or CT disorder as affected. Results in several other regions also provide moderate
evidence (5logP 12.0) of additional susceptibility loci for TD.
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Tourette disorder (TD, or Gilles de la Tourette syndrome
[MIM #137580]) is a childhood-onset chronic neuropsy-
chiatric disorder characterized by multiple motor and
phonic tics that wax and wane over time.1 Once thought
to be rare, with prevalence estimates ranging from 1:
20,000 to 1:2,000,2 it has recently been observed that, in
school-age populations, the prevalence may be as high as
1% among boys.3 Family studies4–6 demonstrate that TD
is familial, and twin studies provide evidence that genetic
factors are important in its transmission.7,8 Initial complex
segregation analyses of nuclear family study data were
consistent with autosomal dominant inheritance.9,10 How-
ever, subsequent studies5,11–13 suggest that the mode of in-
heritance is more complex. Evidence from several genetic
epidemiologic studies has pointed to a common genetic
basis for TD, chronic-tic (CT) disorder, and obsessive-com-
pulsive disorder (OCD).14 When these diagnoses are con-
sidered together, bilineal transmission is common in fam-
ilies ascertained for probands with TD.5,15–17
The likelihood that some forms of TD, CT disorder, and
OCD appear to be variant expressions of the same genetic
susceptibility factors complicates linkage studies of TD
and may partially explain the equivocal results of such
studies, particularly those performed using parametric an-
alyses.14 It is also difficult to compare the results of several
independent linkage studies that have been performed in
extended pedigrees affected with TD, since these have of-
ten employed different parametric models and have used
marker sets that were substantially nonoverlapping.
Given the complications in genetic analyses of TD in
large pedigrees, the Tourette Syndrome Association Inter-
national Consortium for Genetics (TSAICG) undertook a
complementary approach and started a multisite collec-
tion of affected sib pairs (ASPs). An initial linkage analysis
of 92 ASPs from 76 nuclear families provided moderate
evidence (maximum LOD score [MLS] 12) of linkage in
two regions: one on chromosome 4q with a peak MLS ∼3
cM telomeric of D4S1625 and two adjacent segments on
chromosome 8 bounded by markers D8S1106, D8S1145,
and D8S136.18 The TSAICG has extended this prior work
by collecting a larger sample of ASPs for genome screening.
We report here the results of a complete genome screen
that used 390 highly polymorphic DNA markers in a sam-
ple that includes 304 independent ASPs (from 238 nuclear
families) and 18 large multigenerational pedigrees. The
major rationale for including both ASPs and large families
is that it provides the first uniform analysis of the majority
of large pedigrees reported so far for TD. Data from the
large pedigrees, collected by members of the TSAICG with
the use of similar assessment protocols, have now been
evaluated using the same markers and by nonparametric
analysis methods that were not available when the initial
studies of these pedigrees were conducted. Furthermore,
the ASP and large family samples can easily be combined
for further exploration of any linkage findings in each of
the samples separately.
Material and Methods
Sample
Data from 238 ASP families and 18 large multigenerational fam-
ilies (a total of 2,040 individuals: 1,052 in the ASP sample and
988 in the multigenerational family sample) were analyzed in the
genome scan. Of 255 sib-pair families, 17 were excluded from the
analyses either because both sibs did not meet the diagnostic
criteria for TD after complete assessment and consensus diagnosis
( ) or because non-Mendelian inheritance was observed innp 12
the family ( ). Two multigenerational families were excludednp 5
from the large family sample because they were uninformative
for linkage.
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All 238 ASP families included at least two offspring affected
with TD and/or CT disorder. All diagnoses were made using DSM-
IV-TR criteria.1 The ASP families consisted of 182 with two affected
offspring, 47 with three affected offspring, 8 with four affected
offspring, and 1 with five affected offspring, yielding a sample
equivalent to 304 pairwise “independent” sib pairs. An additional
34 unaffected siblings were included in the sample. These indi-
viduals were used to obtain allele-frequency estimates but were
not included in the linkage analyses. As noted above, there were
1,052 individuals in the ASP sample. DNA samples were not ob-
tained from 6 mothers and 27 fathers, which yielded a total of
1,019 individuals for whom genotypes were available for most
loci. There were no families in which DNA was unavailable for
both parents. Of the 33 parents with unavailable DNA, 20 were
also missing phenotypic data. There were 647 individuals (in-
cluding offspring and parents) with TD and 69 with CT disorder
in these families. Of the 716 with a diagnosis of either TD or CT
disorder, 311 also had a diagnosis of OCD. Only 31 individuals
(all parents) received a diagnosis of OCD without TD or CT dis-
order. The 18 multigenerational families range in size from 14
individuals with 3 members affected with TD or CT disorder to
272 individuals with 91 members affected with TD or CT disorder.
Altogether, there were 214 individuals with TD or CT disorder in
these 18 multigenerational families.
This research was approved by the ethics committees of each
participating site. All individuals 18 years and older signed in-
formed consent forms. For those individuals younger than 18,
parents signed consent forms, and the children signed assent
forms before participating.
Phenotypic evaluation.—When a family entered the study, infor-
mation concerning diagnosis was collected as follows. Initially,
information regarding symptoms associated with TD, OCD, and
attention-deficit hyperactivity disorder (ADHD) was obtained
with an interview that included a tic inventory and ordinal se-
verity scales modified from the Yale Global Tic Severity Scale,19
the Diagnostic Confidence Index,20 a Modified Yale-Brown Ob-
sessive-Compulsive Scale,21,22 and the Conners Rating Scales (par-
ent and adult versions).23,24 This interview was then followed by
a comprehensive assessment of other psychopathology, with use
of the Kiddie-SADS–Lifetime Version (K-SADS-PL)25 and the Struc-
tured Clinical Interview for DSM (SCID).26
Earlier versions of the TD and OCD instruments have been
shown to have a high level of agreement with expert clinician
ratings of tic and obsessive-compulsive symptom severity.27–30
These instruments, when compared with clinician diagnoses,
have been shown to be both valid (the rate of agreement between
interview-derived diagnoses and clinical diagnoses was 0.98 for
TD and 0.97 for OCD) and reliable for the diagnoses of TD
( ) and OCD ( ).31 As noted above, for the assess-kp 1.00 kp 0.97
ment of other psychopathology, the K-SADS-PL25 was used for
children younger than 18, and the SCID26 was used for adults.
Both interviews have established reliability. For this report, only
individuals with a diagnosis of TD or CT disorder were considered
to be affected. Future analyses will include information about
OCD, ADHD, and other comorbid conditions.
Best-estimate diagnoses.—All diagnoses were made using the
best-estimate approach.32 Before the initial diagnostic estimate
was made, separate files for each individual were prepared. These
files contain all available information about the individual, in-
cluding the completed interview packet, medical records (if avail-
able), and all reports from relatives. Web-based document access
and data input facilitated the best-estimate consensus diagnostic
process. De-identified records for all families were scanned into
PDF files and made available via password-protected login to cli-
nicians at each of the individual clinical sites on three continents.
Assessment instruments include all materials in the assessment
battery.
Diagnosticians used DSM-IV-TR1 criteria for all disorders. For
each subject in the sample, two diagnosticians—neither from the
originating site of the subject—independently reviewed the as-
sessment materials and recorded diagnoses. A software algorithm
compared diagnoses and notified the clinicians if discrepancies
were found. Clinicians then used e-mail to resolve differences or
to schedule telephone calls for discussion of the differences. In
the rare event of an unresolved disagreement, a third diagnos-
tician was asked to review the case and bring resolution. For cases
in which consensus was not possible because of missing or am-
biguous data, further clinical data were requested from the site
of origin. For the diagnosis of TD and CT disorder, the initial
independent diagnoses of the two consensus diagnosticians were
in agreement 94% of the time (i.e., only 6% of the time was there
a disagreement between the two independent diagnosticians that
required discussion). Failure to reach consensus occurred in only
21 cases, primarily because of the lack of adequate case data. No
individual was included for the linkage study unless consensus
diagnosis was achieved.
DNA Markers
Genotyping was completed at the Centre National de Ge´notypage
in Evry, France. A total of 390 STR markers were genotyped (LMS2
Applied Biosystems). These markers had an average heterozygos-
ity of 0.78. Standard DNA amplification protocols were used and
were optimized to amplify an average of four markers in the same
well.
Fine-mapping genotyping also used standard protocols. Am-
plified products were pooled, depending on the fluorescent dye
label and the size of the products, and were combined with a size
standard before being analyzed on an ABI3730. GeneMapper v3.5
was used to analyze the raw results from the ABI3730. However,
a genotype was not considered final until two laboratory person-
nel had independently checked (and verified or corrected) the
GeneMapper results and had agreed. The rate of missing geno-
types was !4% in both the initial genome scan and the fine-
mapping experiments.
Data Analysis
Automatic genotyping was performed on the basis of a series of
software processes, trace processing, fragment sizing, allele call-
ing, and the assignment of genotype quality scores (QS) that are
implemented in Genetic Profiler software (version 1.1). In addi-
tion, an independent manual review of all samples was also com-
pleted. Two independent readings of all genotypes were com-
pleted. When differences in the genotypes scored in the two
readings were observed, the data were reverified to resolve in-
consistencies. After raw data genotyping analyses were com-
pleted and the results were exported, allele rebinning was per-
formed for each marker on the basis of the distribution of allele
peak locations over all samples in this study. Once final allele
bins were defined, allele codes were assigned for each individual
or microsatellite.
Consistency of the data with Mendelian inheritance, for both
the genome scan and the fine-mapping genotypes, was examined
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Figure 1. Zpairs scores for ASP families, with use of TD (broken line) and TD  CT (solid line) as diagnostic groupings (MERLIN)
using PedCheck.33 Genotypes were reverified when inconsisten-
cies were detected. When the inconsistency could not be resolved,
the family was removed from the study.
The data were also examined to determine whether the removal
of unlikely genotypes would alter the results of linkage analysis.
Unlikely genotypes were identified using the error-checking al-
gorithm implemented in MERLIN,34 which is based on the de-
tection of double-recombinant events. The default parameter,
which identifies erroneous genotypes as those with a likelihood
ratio of , was used. The same procedure was used bothP  .025
for the original markers and for those used in fine mapping. As
expected, given the framework map used in the linkage studies,
there was little difference in the results whether unlikely geno-
types were kept or removed; thus, results are reported for all ge-
notype data.
Analyses were completed using two diagnostic classifications.
The first set of analyses included as affected only those individuals
with a diagnosis of TD (TD). The second set of analyses included
as affected all individuals with a diagnosis of either TD or CT
disorder (TD  CT). Both single-point and multipoint analyses
were completed. Marker-allele frequencies were estimated using
the program MENDEL,35 which uses full-pedigree data and ac-
counts for the nonindependent relationship within the family.
In the single-point analysis, the identity-by-descent distribution
was estimated given the marker genotypes for each marker in-
dividually. In the multipoint analysis, NPL scores were computed
for 14,000 different locations relative to the markers (average step
size !1 cM). All analyses of the ASP families were conducted using
MERLIN.34 For ASP families with more than two affected siblings,
all possible pairs were evaluated, and the results were weighted
by a factor equal to 2/n, where n is the number of affected children
in the sibship. As noted above, the families included in the final
analyses yielded a total of 304 pairwise independent sib pairs.
Analyses of the multigenerational families were conducted with
the computer program SIMWALK2.36–38 Finally, the two samples
were combined and were analyzed using MERLIN and SIM-
WALK2. MERLIN was used to calculate the Z scores in all sib-pair
families and in several multigenerational families, and those re-
sults were then imported, using MEGA2,39 into SIMWALK2, which
was used to analyze the remaining multigenerational families.
For the SIMWALK2 analyses, empirical P values were estimated
by randomly sampling from the very large inheritance-vector
space, to obtain an estimate of pointwise significance. This is in
contrast to other linkage software programs that are constrained
to smaller family units and that calculate an exact P value by
calculating the value of the test statistic for all possible inheri-
tance vectors. In much larger pedigrees, calculating exact P values
is impossible, given the large number of possible inheritance vec-
tors. However, SIMWALK2 can calculate the values for a large
number of the inheritance vectors, thus estimating the pointwise
P value. Analyses were completed using 10,000, 20,000, 40,000,
and 100,000 simulations to estimate significance. The reason for
conducting these analyses was that, for each of the first three sets
of simulations, our most significant result was always equal to
the minimum P value possible for that set of simulations. That
is, for 10,000 simulations, our most significant results corre-
sponded to ( ); for 20,000 simulations,4Pp 1# 10  logPp 4.00
the most significant result observed corresponded to Pp 5#
( ); for 40,000 simulations, the most significant510  logPp 4.30
P value observed was equal to ( ); for52.5# 10  log Pp 4.60
100,000 simulations, the most significant P values observed were
not at the bound of ( ). In addition, the61# 10  logPp 5.00
run time for the Markov chain–Monte Carlo analyses was ex-
tended more than three times the default value in SIMWALK2,
to increase the likelihood of achieving the optimal solution in
the sample of large families. Only the results of the analysis in
which 100,000 simulations were completed are reported.
Results
For both diagnostic classifications, the genome scans of
the ASP sample and the multigenerational family sample
were analyzed separately and together. For the analyses in
the ASP sample in which only individuals with TD were
included as affected, no Zpairs scores 13 were obtained, but
scores 2 (P !1#102) were observed for markers on
chromosomes 2p, 3p, 3q, 4p, 6p, 10p, 15p, 21p, and Xp
(fig. 1). The analysis of the multigenerational family sam-
ple, which included only individuals with TD as affect-
ed, yielded the highest peak on 2p ( , logPp 2.34 Pp
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Figure 2. Zpairs logP scores for the multigenerational pedigrees, with use of TD (broken line) and TD  CT (solid line) as diagnostic
groupings (SIMWALK2).
) at marker D2S165. One other score 12 was34.6# 10
observed on chromosome 5p (fig. 2). For the analyses in
which individuals with either TD or CT disorder were in-
cluded as affected, no NPLpairs scores 13 were obtained in
the ASP sample. Scores 12 ( ) were observed2Pp 2# 10
for markers on chromosomes 2p, 3p, 3q, 4p, 6p, 10p, 11p,
14q, 15p, 20p, 21p, and Xp (fig. 1). Analyses of the mul-
tigenerational families that used the same diagnostic group-
ing (TD  CT) yielded the highest peak on 2p ( logPp
, ) at marker D2S165. Additional scores43.99 Pp 1# 10
12 were observed on chromosomes 5p and 6p (fig. 2). It
should be noted that the highest scores observed in the
ASP sample on 2p for both sets of analyses (TD alone and
TD  CT) were also observed for marker D2S165.
Analysis of the combined sample of ASP and multige-
nerational families slightly increased the linkage signal on
2p for the analyses that included individuals with TD or
CT disorder as affected. For the analyses including only
individuals with TD, the peak at D2S165 was  logPp
( ), compared with 2.34 (43.23 Pp 5.8# 10 Pp 4.6#
) when the data sets were not combined. When in-310
dividuals with TD or CT disorder were included as affected,
the peak at D2S165 was ( , )5 logPp 4.40 Pp 4.0# 10
(fig. 3), compared with 3.99 ( ) when the anal-4Pp 1# 10
yses were completed with the large families alone.
Given these findings, fine mapping on 2p in both ASP
and large families was completed; five additional STR mark-
ers (D2S2233, D2S220, D2S2221, D2S144, and D2S352)
were genotyped at an average spacing of 2 cM. Markers
D2S2233, D2S220, D2S2221, and D2S144 are between
D2S305 and D2S165 (the two markers giving the highest
logP score in the original genome scan data). Marker
D2S352 is between D2S165 and D2S367. The analyses in
the combined sample of ASP and multigenerational
families yielded a maximum Zpairs ( log (P)p 4.42 Pp
) at marker D2S144 with the diagnostic classi-53.8# 10
fication of TD  CT, confirming the findings from the
initial 10-cM genome scan (fig. 4). The 95% CI, calculated
using BINOM,40 for this logP score is 4.01–4.96. Fur-
thermore, support at nearly the same level was maintained
over an ∼5-cM region (sex averaged, encompassing ∼8
Mb). A larger region of ∼16 cM encompasses all markers
with a drop of logP1.
Discussion
The current study represents the largest series of families
with TD to have been included in a genome scan. The
strongest evidence of linkage is at marker D2S144 on chro-
mosome 2p23.2. Moreover, the evidence is strengthened
by the fact that (1) both the sib-pair and the multigener-
ational pedigree samples support linkage to this region
and (2) a more clearly defined linkage peak was observed
when additional markers were typed. An additional piece
of evidence that may support the existence of a TD locus
in this region comes from the observation of a complex
chromosomal rearrangement in which two children with
TD, OCD, and mental retardation inherited an insertion
of 2p21-23 (without any apparent disruption of any genes)
into a region of chromosome 7q35-36.41 This segment of
chromosome 2, which is trisomic in the affected offspring,
contains the 15-Mb interval that lies beneath the linkage
peak (between D2S305 and D2S367). This region has the
highest priority for follow-up studies.
Other regions may also be important to follow up.
When examined separately, several regions emerged as
potentially interesting in the sib-pair sample, with seg-
ments on 3p, 3q, and 14q all displaying NPL scores 12.5.
However, none of these regions were supported substan-
tially by the total multigenerational sample. Similarly, two
regions (5p and 6p) yielded logP scores 12.0 in the ped-
igree sample. Both regions had positive NPL scores in the
ASP sample (5p, ; 6p, ). Of logPp 1.11  logPp 2.42
note is that, in the analyses of the combined samples,
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Figure 3. Zpairs logP scores for the combined sample of ASP and multigenerational families, with use of TD (broken line) and TD 
CT (solid line) as diagnostic groupings (MERLIN and SIMWALK2).
log in the 6p region. Although none of thesePp 2.73
regions achieve statistical significance, they all warrant
additional follow-up, since they may represent the effect
of gene variants that are contributing to TD susceptibility
in only a subset of the families. Given the size of this
sample, it was not computationally feasible to complete
simulations necessary to provide logP scores that define
the thresholds for suggestive and significant linkage. For
example, one complete genome analysis of the combined
data set on a Linux cluster of 30 processors requires 13
mo to complete.
In a previous linkage study, using a subset of the sib
pairs employed in the current genome scan, the TSAICG18
reported moderate evidence of linkage on chromosomes
4q and 8p (MLS 12). A third region on chromosome 4p
showed weak evidence of linkage (MLS 11.0) in that initial
study.18 Of note, in the current study, the evidence of link-
age to 4p is strengthened in both the ASP (Zpairs score 12.0)
and the large family (logP 12.0) samples, as well as in
the combined sample (logP 12.0); however, neither the
region on 4q nor the region on 8p are supported, even in
the ASP sample alone. The diminution of evidence in suc-
cessive linkage studies of complex traits has been observed
for several other disorders.42,43 In addition, theoretical
studies have predicted that this would be the case,44 on
the basis of the inherent etiologic heterogeneity of such
traits, especially where there is variability in either the
ascertainment or the assessment of the subjects. In our
study, we attempted to minimize such variability (e.g.,
through the use of our best-estimate assessment proce-
dures); nevertheless, we ascertained the families for this
study in multiple sites in Europe and North America.
This study also does not provide support for other
regions implicated in prior smaller-scale linkage studies of
TD, some of which focused on families that were included
in the current study. Me´rette and colleagues45 reported
moderate evidence of linkage to chromosome 11q23 in
one large French Canadian kindred. In a genomewide link-
age study of seven multigenerational families, Barr et al.46
observed a linkage signal for TD in two regions (19p13.3
and 5p13-q11.2). Whereas neither of these regions showed
significant linkage in our combined sib-pair and pedigree
analysis, the positive linkage results on chromosome 5 in
the multigenerational families in the current sample are
consistent with the Barr et al. findings.46 However, this
may be due largely to the inclusion of four of the families
from the Barr et al.46 study in the present study. Paschou
and colleagues47 identified suggestive linkage results in
17q (spanning the interval from D17S784 to D17S928) in
three multigenerational families. Although the families in-
cluded in the Paschou et al. study47 are also included in
the current sample, the findings of the combined sample
of ASP and pedigree families and the total pedigree sample
do not support the results of Paschou et al.47
Other approaches have also been employed in the
search for TD susceptibility loci. A recent finding reported
a possible association between the gene “slit and Trk-like
1” (SLITRK1) and TD48; SLITRK1 was examined as a can-
didate gene because of its proximity to a de novo chro-
mosomal inversion on chromosome 13q31.1 in a child
with TD and on the basis of the finding of a frameshift
mutation and two independent occurrences of the iden-
tical variant in the binding site for microRNA hsa-miR-
189 among 174 unrelated probands (but not in 13,600
control chromosomes). Unfortunately, there was no sup-
port for a locus on chromosome 13 in the current study,
suggesting that, if SLITRK1 is a susceptibility gene for TD,
it is not one with major effect in the population studied
and reported in this article.
The fact that we obtained our strongest linkage finding
when we included as affected those individuals with CT
disorder, as well as those given diagnoses of TD, under-
scores the continuing uncertainty regarding the optimal
phenotypic definition for linkage and association studies
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Figure 4. Zpairs logP scores for fine mapping of chromosome 2p, with use of TD and TD  CT as diagnostic groupings (MERLIN and
SIMWALK2). The dotted line represents TD-only genome-scan markers; the dotted and broken line represents TD-only fine-mapping
markers; the broken line represents TD  CT genome-scan markers; and the solid line represents TD  CT fine-mapping markers.
of these disorders. Since we have obtained, in the families
studied, information on other qualitative phenotypes
(e.g., OCD and ADHD) that may be related to TD, as well
as a wide range of quantitative phenotypic features, it will
be possible to conduct further analyses of the genome-
scan data. These analyses may suggest additional genome
regions that warrant follow-up investigation in these fam-
ilies, as well as in the trios with TD that we have sampled.
In conclusion, this sample of 238 ASP families and 18
multigenerational families provides significant evidence
of linkage to marker D2S144 on chromosome 2p32.2.
Other chromosomal regions—including 3p, 3q, and 14q—
had NPL scores 12.5 in the sib-pair sample but not in the
multigenerational pedigrees. These results are consistent
with a complex inheritance model that includes locus het-
erogeneity and a gene of major effect on 2p32.2. Since it
appears likely that other regions may harbor additional
genes that contribute to susceptibility for TD, it is impor-
tant that analyses be undertaken to examine the extent
of linkage heterogeneity and phenotypic variation in this
sample and to attempt to determine if genes in these
regions may be linked in a subset of individuals with TD.
Sib-pair and pedigree samples are most suitable for iden-
tifying relatively infrequent variants of moderate-to-large
effect.49 Given that our collection of such samples has in-
volved an exhaustive international effort, our efforts so
far represent an effective screen for most such variants
that contribute to TD. However, it remains important to
employ different strategies, such as whole-genome asso-
ciation studies, that will facilitate the identification of var-
iants that may have a lesser effect in any given individual
with TD but that will make a relatively larger contribution
to the manifestation of TD in the population as a whole.
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